Aileron Therapeutics, Inc.ALRNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank82
3Y CAGR+97.6%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+97.6%/yr
vs -28.7%/yr prior
Acceleration
+126.3pp
Accelerating
Percentile
P82
Within normal range
vs 3Y Ago
7.7x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202422.07%
202317.32%
20220.86%
20212.86%
2020-24.10%
2019-8.63%
201853.43%
201711.10%
201656.02%
2015-24.53%